The U.S. Patent Office has awarded Sabinsa Corporation, East Windsor, NJ, U.S. patent No. 8193156 for the preparatory route for dipeptides incorporating selenoamino acids. The patent is specific to the preparatory route for L-Selenomethionine peptide having not only a strong vascular endothelial growth factor (VEGF) and anti-5-alpha reductase activity, which are important properties for maintaining perfect homeostasis for “hair care,” but also increased water solubility and bioavailability. This patent represents the 72nd in Sabinsa Corporation’s global patent portfolio.
On the international front, the Japan Patent Office has awarded Sabinsa a patent for the its water-soluble form of naturally available diterpenes derived from Coleus forskolii. The patent covers both the method for solubilizing diterpenes using randomly methylated β-cyclodextrin molecules and applications thereof in glaucoma. Sabinsa will market the product under the name OcuFors.
In other news, the New Zealand Patent Office has awarded Sabinsa a patent (No. 568233) for the company’s SelenoForce, a selenium-enriched garlic product manufactured by a soil-less culture process. The patent, titled “Compositions Containing Allium Sativum Linn. Garlic And A Concentrate Of Organic Selenium Compounds For Nutritional Supplementation,” is valid until December 2026. New Zealand Patent No. 568233 must be included on product labels that contain SelenoForce in New Zealand.
Finally, a three-year-long intellectual property battle has ended with payment to Sabinsa Corporation by Creative Compounds of all profits made through trademark infringement on Sabinsa’s ForsLean together with costs awarded to Sabinsa by the court. Sabinsa alleged that there was a likelihood of confusion between Sabinsa’s registered trademark ForsLean and Creative Compounds’ unregistered mark Forsthin, both of which use Coleus forskohlii extract. In July 2010, the U.S. Court of Appeals overturned a trial court decision that had found no such confusion. Not only did the appellate court reverse the trial court, but also it ordered judgment to be entered in favor of Sabinsa without a new trial. The U.S. District Court of New Jersey awarded Sabinsa damages, ordering Creative Compounds’ profits from its infringement on the ForsLean trademark to be paid to Sabinsa.